Cerevel Therapeutics Holdings Inc reports results for the quarter ended in March - Earnings Summary

Cerevel Therapeutics Holdings

03/05/2023 14:32

* Cerevel Therapeutics Holdings Inc  CERE.OQ  reported a
quarterly
adjusted loss of 67 cents​​ per share for the quarter ended in
March. The mean expectation of eleven analysts for the quarter
was for a loss of 67 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Cerevel Therapeutics Holdings Inc's reported EPS for the
quarter
was a loss of 67 cents​.
    * The mean earnings estimate of analysts had fallen by
about 2.6%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Cerevel Therapeutics Holdings Inc shares had risen
by 26.7% this
quarter and lost 2.0% so far this year.
    * The company reported a quarterly loss of $104.29 million.
    * Wall Street's median 12-month price target for Cerevel
Therapeutics Holdings Inc is $38.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 7 "strong buy" or "buy," 5
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data May
3 at 01:32 p.m. UTC. ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2023      -0.67          -0.67          Met
 Dec. 31 2022      -0.64          -0.59          Beat
 Sep. 30 2022      -0.62          -0.66          Missed
 Jun. 30 2022      -0.48          -0.62          Missed